Esketamine study for depression
Treatments studied
Part of Mental health clinical trials.
This trial tests how treatment with esketamine affects metabolism in people with depression. It may help if you have not responded to at least two standard antidepressants.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have depression and have tried at least two antidepressants at the right dose and duration without success.
- You are not taking tryptophan, St. John's wort, or opioid painkillers in the past month.
- You are not taking daily benzodiazepines.
- You have no psychotic symptoms, alcohol or drug addiction, seizures, eating disorders, dementia, epilepsy, or other serious health conditions like uncontrolled high blood pressure, diabetes, or thyroid disease.
- You are not on a weight loss diet or taking weight loss medication, and you are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether esketamine, a nasal spray for depression, can help adults whose depression has not improved with at least two other antidepressants. Participants continue their current treatment while receiving esketamine.
This early-phase study tests whether ketamine can help people with major depression who have trouble feeling pleasure. It also studies how the brain may change in response to stress, to better understand who might respond to treatment.
This trial tests whether adding ketamine to electroconvulsive therapy (ECT) works better than ECT alone for people with depression that hasn't improved with at least two different antidepressants. It may offer a new option for those who have not found relief from standard treatments.
This study tests a more intensive antidepressant medicine approach for people whose first tried treatment didn’t work well enough. It compares the intensified treatment with usual care, aiming to improve depression symptoms and daily functioning.
This trial tests whether a single dose of ketamine can improve depression by changing how your cells' energy factories (mitochondria) work. It is for people with treatment-resistant depression who haven't found relief from standard antidepressants.
This early-stage study tests ketamine and looks at what brain changes may explain why it helps people with major depression that hasn’t improved with usual treatments. You may be asked to stay in the hospital and complete detailed interviews, mood rating scales, and brain imaging.
Hear when a new Major Depressive Disorder trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.